

Haematologica
HAEMATOL/2019/238394
Version 3

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma

Sandra Maria Dold, Veronika Riebl, Dagmar Wider, Marie Follo, Milena Pantic, Gabriele Ihorst, Justus Duyster, Robert Zeiser, Ralph Wäsch, and Monika Engelhardt

Disclosures: SMD, VR, DW, MF, MP, GI, RZ and JD have no conflicts of interest to disclose. RW has received research and travel support from Sanofi, Gilead, Jazz, Celgene and Amgen, and has received consultancy fees from Sanofi, Pfizer, Gilead, Novartis, Amgen and Takeda. ME has received educational and trial support from Amgen, Celgene, Takeda, BMS, Janssen, Novartis, Karyopharm, and has received honoraria and consultancy fees from BMS, Celgene, Amgen, Takeda, Novartis and Janssen.

Contributions: SMD analyzed the data. SMD and ME wrote the manuscript. SMD, DW, RW, and ME designed the project. SMD, VR and DW measured the samples. GI controlled the statistics and contributed in the statistical analyses of PFS and OS. MP did the routine cytogenetic analyses. MF provided insides into routine flow in MM and flow cytometry. MF provided equipment. DW, RW, VR, RZ, MF, MP and GI revised the manuscript. MP and JD provided the patient samples. RZ, JD, RW and ME supported the project.